1. Home
  2. QNST vs GYRE Comparison

QNST vs GYRE Comparison

Compare QNST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuinStreet Inc.

QNST

QuinStreet Inc.

HOLD

Current Price

$11.90

Market Cap

679.9M

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.82

Market Cap

759.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNST
GYRE
Founded
1999
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
679.9M
759.1M
IPO Year
2009
2004

Fundamental Metrics

Financial Performance
Metric
QNST
GYRE
Price
$11.90
$6.82
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$24.75
$17.00
AVG Volume (30 Days)
747.1K
113.7K
Earning Date
05-06-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.94
0.02
Revenue
$282,140,000.00
$275,000.00
Revenue This Year
$18.59
$27.85
Revenue Next Year
$14.96
$0.80
P/E Ratio
$12.73
$351.00
Revenue Growth
N/A
N/A
52 Week Low
$10.29
$6.11
52 Week High
$19.53
$11.77

Technical Indicators

Market Signals
Indicator
QNST
GYRE
Relative Strength Index (RSI) 49.30 35.90
Support Level $10.54 N/A
Resistance Level $15.52 $8.25
Average True Range (ATR) 0.47 0.61
MACD 0.09 -0.15
Stochastic Oscillator 54.10 4.62

Price Performance

Historical Comparison
QNST
GYRE

About QNST QuinStreet Inc.

QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: